<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555655</url>
  </required_header>
  <id_info>
    <org_study_id>BEC-CMI-003</org_study_id>
    <nct_id>NCT04555655</nct_id>
  </id_info>
  <brief_title>The Effects of Chicken Extract and a Peptide Supplement for the Prevention of Cognitive Decline in Non-demented Elderly Adults</brief_title>
  <official_title>Trial of A Chicken Extract and Peptide Supplement for the Prevention of Cognitive Decline and Mechanisms of Action in Non-demented Elderly Adults: A Multicenter, Two-year, Three-arm, Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brand's Suntory Asia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taipei Medical University Shuang Ho Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brand's Suntory Asia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates the effect of a chicken extract supplement and a peptide supplement&#xD;
      on cognitive function and potential mechanisms of action of cognitive decline during ageing,&#xD;
      among non-demented elderly adults using a three-arm, randomized, placebo-controlled clinical&#xD;
      trial design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Function assessed by Alzheimer's Disease Composite Score (ADCOMS)</measure>
    <time_frame>24 months</time_frame>
    <description>Change from baseline in Alzheimer's Disease Composite Score (ADCOMS).&#xD;
ADCOMS composite score is a weighted linear combination of the 12 items in the Wold's partial least squares (PLS) model. Composite scores range from 0.0 to a maximum of 1.97, where higher values indicate worse performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Florbetaben (18F) PET Scan Imaging</measure>
    <time_frame>24 months</time_frame>
    <description>Change from baseline values in Florbetaben (18F) PET scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Handgrip strength</measure>
    <time_frame>12 months &amp; 24 months</time_frame>
    <description>Change from baseline in handgrip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of plasma tau protein and amyloid-beta 42</measure>
    <time_frame>24 months</time_frame>
    <description>Change from baseline in plasma tau protein &amp; amyloid-beta 42 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Composite Score (ADCOMS)</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in Alzheimer's Disease Composite Score (ADCOMS). ADCOMS composite score is a weighted linear combination of the 12 items in the Wold's partial least squares (PLS) model. Composite scores range from 0.0 to a maximum of 1.97, where higher values indicate worse performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood myeloperoxidase (MPO) levels</measure>
    <time_frame>12 months &amp; 24 months</time_frame>
    <description>Change from baseline in blood myeloperoxidase (MPO) Higher levels of MPO indicate worse oxidative stress status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood inflammation biomarker levels (hs-CRP, ESR, TNF-α, IL-6)</measure>
    <time_frame>12 months &amp; 24 months</time_frame>
    <description>Change from baseline in inflammation, measured by the following blood biomarkers. Each biomarker will be evaluated individually.&#xD;
High-sensitivity C-reactive Protein (hs-CRP)&#xD;
Erythrocyte Sedimentation Rate (ESR)&#xD;
Tumor necrosis factor alpha (TNFα)&#xD;
Interleukin 6 (IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose level</measure>
    <time_frame>4, 8, 12, 18 and 24 months</time_frame>
    <description>Change from baseline in fasting blood glucose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Taiwanese Depression Questionnaire (TQD) score</measure>
    <time_frame>4, 8, 12, 18 and 24 months</time_frame>
    <description>Change from baseline in patient-reported Taiwanese Depression Questionnaire (TQD) scores.&#xD;
TDQ scores range from 0 to 54, with the higher score indicating the greater depression state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36) Component and Scale Scores</measure>
    <time_frame>4, 8, 12, 18 and 24 months</time_frame>
    <description>Change from baseline in Short Form-36 (SF-36) Component and Scale Scores. Each scale is directly transformed into a 0 - 100 scale on the assumption that each question carries equal weight. Lower score indicates more disability/worse health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Athens Insomnia Scale (AIS)</measure>
    <time_frame>4, 8, 12, 18 and 24 months</time_frame>
    <description>Change from baseline in Athens Insomnia Scale Score. A composite score which ranges from 0-24 will be evaluated. Higher score stands for greater severity of insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>24 months, reported at each study visit (4, 8, 12, 18 and 24 months)</time_frame>
    <description>Number and incidence of infections occurring during the study period according to a self-reported infection survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral blood flow measured with sonography</measure>
    <time_frame>12 months &amp; 24 months</time_frame>
    <description>Mean values of cerebral blood flow measured with sonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (systolic blood pressure and diastolic blood pressure)</measure>
    <time_frame>4, 8, 12, 18 and 24 months</time_frame>
    <description>Change from baseline in systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Cognitive Decline</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Chicken extract supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Peptides supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chicken extract supplement</intervention_name>
    <description>70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.</description>
    <arm_group_label>Chicken extract supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Peptide Supplement</intervention_name>
    <description>70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.</description>
    <arm_group_label>Peptides supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female at 55 - 75 years of age&#xD;
&#xD;
          -  Baseline cognition:&#xD;
&#xD;
          -  Normal cognition with feelings of cognitive decline (subjective cognitive decline) OR&#xD;
&#xD;
          -  Mild cognitive impairment (MCI+) with memory impairment&#xD;
&#xD;
          -  Agree to participate in the study and provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate visual and auditory acuity to allow neuropsychological testing&#xD;
&#xD;
          -  Significant cerebrovascular disease&#xD;
&#xD;
          -  History of allergy to chicken meat&#xD;
&#xD;
          -  Diagnosis of Alzheimer's disease (AD) with dementia or any other dementia&#xD;
&#xD;
          -  Clinical dementia rating (CDR) score of &gt; 0.5 at screening&#xD;
&#xD;
          -  Evidence of other neurological, psychiatric or physical illness that can produce&#xD;
             cognitive deterioration per investigator's judgment&#xD;
&#xD;
          -  Inability or unwillingness to undergo PET scan&#xD;
&#xD;
          -  Current diagnosis or history of alcoholism or substance addiction&#xD;
&#xD;
          -  Regular use of any medication in the past 6 months that may affect cognitive&#xD;
             functioning&#xD;
&#xD;
          -  Regular use of cognitive enhancing supplements in the past 6 months&#xD;
&#xD;
          -  Subjects with excessive blood donation or blood drawn prior to baseline&#xD;
&#xD;
          -  Persons with a history of cardiovascular disease or any other cardiovascular or&#xD;
             cerebrovascular diseases which investigators deem unsuitable to participate in the&#xD;
             clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mandy Ow, PhD</last_name>
    <phone>+65-8158-8866</phone>
    <email>mandy.ow@brands-suntory.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Medical University Hospital Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hu Chaur-Jong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pai Ming-Chyi, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taoyuan Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsu Wen-Chuin, MD,MS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

